Last checked at 9 Aug 2019 12:00
Notice of Interim Results
London, UK - 9 August 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2019 on Wednesday 4 September 2019.
A briefing for analysts will be held at 13:00 BST / 08:00 EST on the day of results at 85 Gresham Street, London EC2V 7NQ. There will also be a live webcast with a Q&A session. The presentation and webcast details will be made available on the Group's website at www.oxb.com. A replay of the presentation will be made available shortly afterwards.
Please contact Consilium Strategic Communications for further details.
- Ends -
Enquiries: |
|
Oxford Biomedica plc
Catherine Isted, Head of Corporate Development & IR Sarah MacLeod, Head of Communications
|
T: +44 (0)1865 954161 / E: ir@oxb.com T: +44 (0)1865 783016 / E: media@oxb.com |
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal |
T: +44 (0)20 3709 5700 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform, LentiVector®, which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs over 430 people. Further information is available at www.oxb.com